ACLX News and Press, Arcellx Inc.

2026-04-24 10:04:29 ET So, since my November article , " Legend Biotech: Is Carvykti Changing Cancer Treatment Forever?, " Legend Biotech Corporation ( LEGN ) stock has traded down 14.9%, underperforming the iShares Biotechnology ETF ( IBB ) (1.5% return), as well as the...

2026-04-20 11:55:48 ET More on Health Care stocks IHI: Pullback Creates A Buying Opportunity In High-Growth MedTech Routine Vaccines Okay For Now: Investment Implications Of The Court Decision Sector Rotation: Healthcare XLV Should Be The Next Stop Cybin stan...

2026-04-17 09:17:25 ET More on Gilead Sciences, Arcellx Gilead Sciences Is Doubling Down On Acquisitions Gilead Sciences, Inc. (GILD) Discusses Proposed Acquisitions of Tubulis, Ouro and Arcellx and Strategic Pipeline Expansion Transcript Gilead Sciences, Inc. (GILD)...

2026-04-10 10:09:32 ET More on Gilead Sciences Gilead Sciences Is Doubling Down On Acquisitions Gilead Sciences, Inc. (GILD) Discusses Proposed Acquisitions of Tubulis, Ouro and Arcellx and Strategic Pipeline Expansion Transcript Gilead Sciences, Inc. (GILD) Discusse...

2026-04-07 09:21:33 ET More on Gilead Sciences Gilead Sciences: Caution After A Re-Rating Amidst New Concentration Risks Gilead extends Arcellx tender offer expiration date Galapagos NV, Gilead Sciences strike deal tied to Ouro Medicines acquisition Read th...

2026-04-03 08:38:43 ET Arcellx, Inc. ( NASDAQ:ACLX – Get Free Report )’s share price hit a new 52-week high during trading on Wednesday . The company traded as high as $114.94 and last traded at $114.8950, with a volume of 455581 shares traded. The stock had previously...

2026-04-01 16:31:12 ET More on Gilead Sciences Gilead Sciences, Inc. (GILD) M&A Call Transcript Gilead Sciences: Caution After A Re-Rating Amidst New Concentration Risks Gilead: Why The 'Immune System Company' Pivot Is No Longer A Bargain (Downgrade) Gala...

Are ACLX, MASI, FONR Obtaining Fair Deals for their Shareholders? PR Newswire Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers. Sha...

2026-03-16 19:33:01 ET On February 17, 2026, Cormorant Asset Management disclosed in a regulatory filing that it sold its entire stake in Arcellx (NASDAQ:ACLX) , an estimated $63.63 million transaction based on last-disclosed position values. According to an SEC filing dated...

Are MASI, ACLX, GLDD Obtaining Fair Deals for their Shareholders? PR Newswire Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers. Sha...